Search

Displaying results 3861 - 3870 of 10000 in total
  1. Drug

    Acapatamab

    go.drugbank.com/drugs/DB18838
    Investigational

    Acapatamab is under investigation in clinical trial NCT04631601 (Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (Mcrpc)).

    Synonyms: (scfv)2-scfc, bispecific, Mmunoglobulin scfv-scfv-scfc, anti-(homo sapiens folh1 (folate hydrolase, prostate specific membrane antigen, psma)) and anti-(homo sapiens cd3e (cd3 epsilon, leu-4)), monoclonal antibody single chain
  2. Drug

    Fosigotifator

    go.drugbank.com/drugs/DB19409
    Investigational

    Fosigotifator is under investigation in clinical trial NCT05757141 (An Open-label Exploratory Study of ABBV-CLS-7262 Subjects With Vanishing White Matter Disease).

    Synonyms: Sodium ({(2S)-1,4-bis[2-(4-chloro-3- fluorophenoxy)acetamido]bicyclo[2.2.2]octan-2- yl}oxy)methyl hydrogen phosphate - 2-amino-2- (hydroxymethyl)propane-1,3-diol (1/1/1)
  3. Drug

    Phenaglycodol

    go.drugbank.com/drugs/DB19373
    Experimental

    Synonyms: 2,3-butanediol, 2-(4-chlorophenyl)-3-methyl-, (+/-)-2-(p-chlorophenyl)-3-methyl-2,3-butanediol
  4. Drug

    Liraglutide

    go.drugbank.com/drugs/DB06655
    ApprovedInvestigational

    Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist. … [A6932] Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor.

    Mixtures: XULTOPHY 100U/ML+3.6MG/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 1 ADET, XULTOPHY 100U/ML+3.6MG/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 3 ADETCategories: Glucagon-like peptide-1 (GLP-1) analogues, GLP-1 Agonists
  5. Drug

    Zimberelimab

    go.drugbank.com/drugs/DB17505
    Investigational

    Synonyms: Immunoglobulin g4(231-proline), anti-(human programmed cell death protein 1) (human monoclonal ab122 .gamma.4-chain), disulfide with human monoclonal ab122 .lambda.-chain, dimer, Anti-pd-1 monoclonal antibody gls-010
  6. Drug

    Baricitinib

    go.drugbank.com/drugs/DB11817
    ApprovedInvestigational

    Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. … [A248400] The EC later approved baricitinib for the treatment of atopic dermatitis, making it the first JAK inhibitor used for this indication in Europe.

    Categories: MATE 2 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexProducts: UNAMİTY 4 MG FİLM KAPLI TABLET, 7 ADET, UNAMİTY 4 MG FİLM KAPLI TABLET, 14 ADET
  7. Drug

    Dexketoprofen

    go.drugbank.com/drugs/DB09214
    ApprovedInvestigationalWithdrawn

    Dexketoprofen is a non-steroidal anti-inflammatory drug. It is available in the various countries in Europe, Asia and Latin America.

    International brands: KETRON DMixtures: DEKSİT 25 MG/4 MG TABLET, DETROİTS 25 MG/4 MG FİLM KAPLI TABLET, 15 TABLET
  8. Drug

    Atilotrelvir

    go.drugbank.com/drugs/DB19439
    Investigational

    Atilotrelvir is under investigation in clinical trial NCT05041907 (Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)).

    Synonyms: (1R,4S,6S)-N-{(1S)-1-ciano-2-[(3S)-2-oxopirrolidin-3-il]etil}-5-[(2S)-3,3-dimetil-2-(2,2,2-trifluoroacetamido)butanoil]-5-azaespiro[biciclo[2.2.1]heptano-2,1'-ciclopropano]-6-carboxamida, Spiro[2-azabicyclo[2.2.1]heptane-5,1′-cyclopropane]-3-carboxamide, N-[(1S)-1-cyano-2-[(3S)-2-oxo-3-pyrrolidinyl]ethyl]-2-[(2S)-3,3-dimethyl-1-oxo-2-[(2,2,2-trifluoroacetyl)amino]butyl]-, (1S,3S,4R)-
  9. Drug

    AZD2315

    go.drugbank.com/drugs/DB06540
    Experimental

    The drug AZD2315, an immunosuppressant developed by AstraZeneca, was in Phase 1 clinical trials for the treatment of rheumatoid arthritis but was discontinued during this phase

    Synonyms: L-ALANINAMIDE, N-(1-OXO-5-PHENYLPENTYL)-L-ALANYL-L-ARGINYL-L-ALANYL-(.ALPHA.S,3R)-3-AMINO-.ALPHA.-METHYL-2-OXO-1-PYRROLIDINEACETYL-L-ALANYL-L-ARGINYL-N-(4-(2-AMINO-2-OXOETHYL)PHENYL)-, ACETATE (1:2), L-ALANINAMIDE, N-(1-OXO-5-PHENYLPENTYL)-L-ALANYL-L-ARGINYL-L-ALANYL-(.ALPHA.S,3R)-3-AMINO-.ALPHA.-METHYL-2-OXO-1-PYRROLIDINEACETYL-L-ALANYL-L-ARGINYL-N-(4-(2-AMINO-2-OXOETHYL)PHENYL)-, DIACETATE
  10. Drug

    scAAV9.U7.ACCA

    go.drugbank.com/drugs/DB18582
    Investigational

    scAAV9.U7.ACCA is a non-replicating recombinant adeno-associated virus vector containing 4 antisense sequences designed to target exon 2 in the human DMD gene under the control of U7 small nuclear non-coding

    Synonyms: non-replicating recombinant adeno-associated virus vector containing 4 antisense sequences designed to target exon 2 in the human DMD gene under the control of U7 small nuclear non-coding RNA